This new board brings diverse expertise in biologics development and commercialization, new technologies, contract services and a deep understanding of the key challenges facing biologics developers, both now and in the future.
Somerset, N.J. (PRWEB) August 05, 2015
Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has formed an advisory board to strategically shape growth of the company’s biologics business.
Founding members of the advisory board are: Carolyn Bertozzi, Ph.D., Barry Buckland, Ph.D., Michael Buckley, Ph.D., Daniel R. Marshak, Ph.D., and Edward R. Robinson.
“This new board brings diverse expertise in biologics development and commercialization, new technologies, contract services and a deep understanding of the key challenges facing biologics developers, both now and in the future,” commented Mike Riley, Vice President and General Manager of Catalent Biologics. He added “Catalent Biologics has developed a unique combination of proprietary technology platforms and integrated services to enable our partners’ next generation of biologics treatments. These expert advisors will play a key role in guiding our strategy as we continue to build our biopharma solutions offerings.”
Carolyn Bertozzi, Ph.D. is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. Dr. Bertozzi is the recipient of numerous honors and awards for her research, including a MacArthur Foundation Fellowship and was the first woman awarded the Lemelson-MIT award for inventors. She is an elected member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts and Sciences, and the German Academy of Sciences Leopoldina. She co-founded Redwood Bioscience, which was acquired by Catalent in 2014, and currently serves as the Chair of Redwood’s Scientific Advisory Board.
Barry Buckland, Ph.D. spent approximately 30 years at Merck & Co., most recently as Vice President and head of the Bioprocess R&D organization at Merck Research Laboratories and was involved in the development and launch of key products including Recombivax HB® and Gardasil®. Dr. Buckland is a member of the National Academy of Engineering, and is the recipient of numerous awards including PhRMA’s Discoverers Award for the development of Gardasil and the American Chemical Society’s Marvin Johnson Award for Lifetime Achievement in Biotechnology.
Michael Buckley, Ph.D. has over 30 years of experience in the biotech industry, most recently serving as Vice President of Core Technology and Vice President of Process Sciences at Takeda Pharmaceuticals. Dr. Buckley previously held executive positions with Neugenesis Corporation, Genitope Corporation and Corixa Corporation, where he was instrumental in the development of the first centrally manufactured radiopharmaceutical-Iodine-131 antibody.
Daniel R. Marshak, Ph.D. currently serves as a Director on the Board of InVivo Therapeutics, a medical device and biotechnology company in Cambridge, MA. He most recently served as Senior Vice President and Chief Scientific Officer for Perkin Elmer, Inc., and previously served as Vice President and Chief Technology Officer, Biotechnology, for Cambrex Corporation and Senior Vice President and Chief Scientific Officer of Osiris Therapeutics where he led stem cell research from inception to late stage clinical trials. Dr. Marshak currently serves on the International Society for Stem Cell Research Global Advisory Council, and recently held an appointment as Adjunct Associate Professor at the Johns Hopkins University School of Medicine. Dr. Marshak was previously Senior Staff Investigator at Cold Spring Harbor Laboratory and Assistant Professor at the State University of New York, Stony Brook.
Edward R. Robinson is currently Chairman & CEO of Acadia Harvest, and has over 30 years of experience in the biotech industry. Mr. Robinson previously served as an Executive Vice President at Cambrex Corporation, President of Solutia Pharmaceutical Services, and President of Lonza Biologics where he tripled the size of the business over a three year period and was instrumental in launching Lonza’s US operations.
The new advisory board will complement the existing Redwood Bioscience Scientific Advisory Board, consisting of key thought leaders in biologics development and protein chemistry including: Benjamin G. Davis, Ph.D., Professor of Chemistry at Oxford University and one of the world’s leading experts in the chemical understanding and exploitation of biomolecular function, Tom Muir, Ph.D., Professor of Chemistry at Princeton University and one of the world’s leading experts in protein chemistry for bioconjugation, Andrew D. Simmons, Ph.D., who brings 20 years of pharmacology experience with Takeda, Cell Genesys and Clovis Oncology, and Ted Yednock, Ph.D., currently CSO of Annexon Biosciences, who was previously Executive Vice President and Head of Global Research for Elan Pharmaceuticals and the scientific inventor of Tysabri®, a marketed monoclonal antibody for MS.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 30 facilities across 5 continents, and in fiscal 2014 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™